I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Short position through short-selling of the ...

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Jonathan Dickinson - Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Daina Graybosch - Leerink Partners Rajan Sharma - Goldman Sachs Arthur He - ...

| --- | --- | --- | |-----------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Q3 2024 Business Update and | | | | Financial Results | | | | 13 November 2024 | | | | | | | Disclaimer on Forward-Looking Information and Risk Factors 2 This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document c ...

Innate Pharma S.A. (NASDAQ:IPHA) Q2 2024 Earnings Conference Call September 12, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Herve Brailly - Interim Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Rajan Sharma - Goldman Sachs Daina Graybosch - Leerink Partners Ashiq M ...

INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2024 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,049,171.60 euros composed of 80,969,357 ordinary shares, and 14,075 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Company and Trade Register of Marseille under number 424 365 336 The following interim condensed consolidated financia ...

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2024 Results Conference Call May 14, 2024 8:00 AM ET | --- | |-------------------------------------------------| | | | Henry Wheeler - Head, Investor Relations | | Herve Brailly - Interim Chief Executive Officer | | Sonia Quaratino - Chief Medical Officer | | Yannis Morel - Chief Operating Officer | | Arvind Sood - EVP, U.S. Operations | | Frederic Lombard - Chief Financial Officer | | Conference Call Participants | | Daina Graybosch - Leerink Partners | | Yigal Nochomovi ...

Innate Pharma S.A. Sponsored ADR (IPHA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Indiv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Results Conference Call March 21, 2024 9:00 AM ET Conference Call Participants And I will now turn the conference over to Henry Wheeler, Vice President of Investor Relations. Mr. Wheeler, you may begin. This morning, Innate issued a press release for our full year 2023 financial results and business update. We look forward to highlighting the progress made during the year-to-date as well as addressing future goals and milestones. The press release and today's present ...

EXHIBIT 99.1 Summary of Consolidated Financial Statements and Notes as of December 31, 2023 Consolidated Statements of Financial Position (in thousand euros) | | December 31, 2023 | December 31, 2022 | | --- | --- | --- | | Assets | | | | Cash and cash equivalents | 70,605 | 84,225 | | Short-term investments | 21,851 | 17,260 | | Trade receivables and others - current | 55,557 | 38,346 | | Total current assets | 148,012 | 139,831 | | Intangible assets | 416 | 1,556 | | Property and equipment | 6,322 | 8,542 ...